本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

BridgeBio Pharma, Inc.

31.37
-2.7000-7.92%
盘后31.03-0.3400-1.08%17:35 EDT
成交量:401.52万
成交额:1.28亿
市值:59.66亿
市盈率:-10.90
高:33.89
开:33.37
低:30.86
收:34.07
数据加载中...

公司资料

公司名字:
BridgeBio Pharma, Inc.
交易所:
NASDAQ
成立时间:
2015
员工人数:
728
公司地址:
3160 Porter Drive,Suite 250,Palo Alto,California,United States
邮编:
94304
电话:
传真:
- -
简介:
BridgeBio Pharma, Inc.于2019年5月17日在特拉华州成立。该公司是一家处于商业阶段的生物制药公司,旨在发现、创造、测试和提供具有变革性的药物,以治疗具有明确遗传驱动因素的遗传性疾病和癌症患者。

董事

名称
职位
Charles Homcy
Chairman of Pharmaceuticals, Director
Frank McCormick
Chairman of Oncology
Neil Kumar
Chief Executive Officer, Director
Richard H. Scheller
Chairman of Research & Development, Director
Ali J. Satvat
Director
Eric Aguiar
Director
James C. Momtazee
Director

股东

名称
职位
Neil Kumar
Chief Executive Officer, Director
Brian C. Stephenson
Chief Financial Officer
Cameron Turtle
Senior Vice President, Portfolio Management and Corporate Development
Michael Henderson
Senior Vice President, Asset Acquisition, Strategy and Operations
Uma Sinha
Chief Scientific Officer